Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Alone or in Combination With Bevacizumab or Ipilimumab Before Surgery in Metastatic Renal Cell Carcinoma
NCT02210117Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2014
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nivolumab in renal cell carcinoma (RCC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 6 weeks. Started Nov 2014; status: active, not recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02210117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210117.